Study Information for: "Study of the Effectiveness and Safety of Ocrelizumab in Adults with Early Stage Relapsing Remitting Multiple Sclerosis" - Be Involved

What we are studying

The purpose of this study is to see if Ocrelizumab (study drug) will halt the worsening of the signs and symptoms of early stage MS.

Who we are studying

Men and Women
Races:
- White
- African American
- Asian
- American Indian or Alaska Native
- Native Hawaiian or Pacific Islander
- Other
All Ethnicities
Ages 18 - 55

Eligibility Criteria

Have a definite diagnosis of Relapsing Remitting Multiple Sclerosis
Have a length of disease duration of less than or equal to 3 years
Had one or more clinical relapses within the last 12 months

What is involved

Visits to the Neurology Outpatient Clinic for assessments in addition to 9 visits to the CRU for study drug administration
Neurological Exams
Questionnaires
Telephone visits
MRI

Compensation

You will be paid $1200.00 if you complete all the scheduled study visits. If you withdraw for any reason from the study before completion you will be paid $100.00 for each complete study visit.